share_log
Breakings ·  Nov 26 20:00
Axsome Therapeutics Announces Axs-12 Achieves Primary Endpoint in Encore Long-Term Phase 3 Trial in Narcolepsy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment